Equities Analysts Offer Predictions for TRAX Q3 Earnings

First Tracks Biotherapeutics (NASDAQ:TRAX) – Equities researchers at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of First Tracks Biotherapeutics in a research note issued on Thursday, August 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.96) per share for the quarter, down from their previous forecast of ($0.90). HC Wainwright has a “Buy” rating and a $57.00 price objective on the stock. The consensus estimate for First Tracks Biotherapeutics’ current full-year earnings is ($4.02) per share. HC Wainwright also issued estimates for First Tracks Biotherapeutics’ Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($4.35) EPS, FY2027 earnings at ($3.83) EPS, FY2028 earnings at ($3.84) EPS, FY2029 earnings at ($2.80) EPS and FY2030 earnings at ($2.17) EPS.

TRAX has been the topic of several other reports. Leerink Partners assumed coverage on shares of First Tracks Biotherapeutics in a report on Friday, April 24th. They set an “outperform” rating and a $46.00 price target on the stock. Piper Sandler upped their target price on First Tracks Biotherapeutics from $54.00 to $95.00 and gave the stock an “overweight” rating in a research report on Thursday. Wells Fargo & Company raised their price target on First Tracks Biotherapeutics from $30.00 to $55.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. began coverage on First Tracks Biotherapeutics in a report on Thursday, April 23rd. They set an “overweight” rating and a $31.00 price target for the company. Finally, Wedbush boosted their price target on First Tracks Biotherapeutics from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, First Tracks Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $60.50.

First Tracks Biotherapeutics Price Performance

Shares of TRAX opened at $43.60 on Monday. The stock has a market capitalization of $1.56 billion and a P/E ratio of -23.70. The company’s 50 day moving average is $30.95. First Tracks Biotherapeutics has a 52 week low of $14.72 and a 52 week high of $49.91.

First Tracks Biotherapeutics (NASDAQ:TRAX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.21).

First Tracks Biotherapeutics Company Profile

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.